Common Contracts
3 similar Securities Purchase Agreement contracts by Champions Oncology, Inc.
AMENDED AND RESTATED 2011 SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 17th, 2015 • Champions Oncology, Inc. • Biological products, (no disgnostic substances) • New York
This AMENDED AND RESTATED 2011 SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of March 13, 2015, by and between Champions Oncology, Inc. (the “Company”) (previously known as Champions Biotechnology, Inc.), Battery Ventures IX, L.P. (“Ventures”), Battery Investment Partners IX, LLC (together with Ventures, “Battery”), Joel Ackerman (“Ackerman”) and Ronnie Morris (“Morris”) amends and restates in its entirety the Securities Purchase Agreement dated as of March 24, 2011 (the “Original 2011 Securities Purchase Agreement”) between the Company, Battery, Ackerman, Morris and the other parties to the Original 2011 Securities Purchase Agreement (such parties, Battery, Ackerman and Morris being the “Investors”), as amended by the Amendment No. 1 to 2011 Securities Purchase Agreement dated January 29, 2014.
AMENDED AND RESTATED 2013 SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 17th, 2015 • Champions Oncology, Inc. • Biological products, (no disgnostic substances) • New York
This AMENDED AND RESTATED 2013 SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of March 13, 2015, by and between Champions Oncology, Inc., a Delaware corporation (the “Company”), Battery Ventures IX, L.P., a Delaware limited partnership (“Ventures”), Battery Investment Partners IX, LLC, a Delaware limited liability company (together with Ventures, “Battery”), PAR Investment Partners, L.P., a Delaware limited partnership (“PAR”), Joel Ackerman (“Ackerman”) and Ronnie Morris (“Morris”) amends and restates in its entirety the Securities Purchase Agreement dated as of January 28, 2013 (the “Original 2013 Securities Purchase Agreement”) between the Company, Battery, PAR, Ackerman, Morris and the other parties to the Original 2013 Securities Purchase Agreement (such parties, Battery, PAR, Ackerman and Morris being the “Investors”), as amended by the Amendment No. 1 to 2013 Securities Purchase Agreement dated January 29, 2014.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 30th, 2013 • Champions Oncology, Inc. • Biological products, (no disgnostic substances) • New York
SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 28, 2013, by and between Champions Oncology, Inc., a Delaware corporation (the “Company”), Battery Ventures IX, L.P., a Delaware limited partnership (“Ventures”), Battery Investment Partners IX, LLC, a Delaware limited liability company (together with Ventures, “Battery”), PAR Investment Partners, L.P., a Delaware limited partnership (“PAR”) and the parties listed on the Schedule of Investors attached hereto (the “Schedule of Investors”) (each hereinafter individually referred to as an “Investor” and collectively, together with Battery and PAR unless otherwise indicated, referred to as the “Investors”).
